Suheung Co., Ltd. (008490.KS)
KRW 12880.0
(-1.68%)
KRW 12880.0
(-1.68%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 77.02 Billion KRW | -23.07% |
| 2022 | 98.6 Billion KRW | -15.48% |
| 2021 | 114.88 Billion KRW | 5.75% |
| 2020 | 110.4 Billion KRW | 36.12% |
| 2019 | 80.14 Billion KRW | 21.82% |
| 2018 | 69.7 Billion KRW | 9.71% |
| 2017 | 62.65 Billion KRW | -4.19% |
| 2016 | 61.46 Billion KRW | 20.05% |
| 2015 | 53.61 Billion KRW | 9.08% |
| 2014 | 50.9 Billion KRW | 16.41% |
| 2013 | 42.8 Billion KRW | 37.22% |
| 2012 | 17.59 Billion KRW | -14.02% |
| 2011 | 36.7 Billion KRW | -6.5% |
| 2010 | 39.34 Billion KRW | 7.37% |
| 2009 | 35.17 Billion KRW | 13.35% |
| 2008 | 29.44 Billion KRW | 50.05% |
| 2007 | 27.97 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 20.71 Billion KRW | -3.2% |
| 2024 Q1 | 21.57 Billion KRW | 133.36% |
| 2023 Q4 | 13.62 Billion KRW | -43.78% |
| 2023 FY | - KRW | -23.07% |
| 2023 Q1 | 27.38 Billion KRW | 132.22% |
| 2023 Q2 | 30.76 Billion KRW | 12.34% |
| 2023 Q3 | 24.23 Billion KRW | -21.24% |
| 2022 Q2 | 30.67 Billion KRW | 9.14% |
| 2022 Q3 | 32.56 Billion KRW | 6.15% |
| 2022 Q4 | 11.79 Billion KRW | -63.79% |
| 2022 Q1 | 28.1 Billion KRW | -1.43% |
| 2022 FY | - KRW | -15.48% |
| 2021 Q3 | 23.66 Billion KRW | -33.29% |
| 2021 Q4 | 28.51 Billion KRW | 20.48% |
| 2021 FY | - KRW | 5.75% |
| 2021 Q1 | 34.32 Billion KRW | 73.55% |
| 2021 Q2 | 35.47 Billion KRW | 3.36% |
| 2020 Q1 | 30.15 Billion KRW | 85.39% |
| 2020 FY | - KRW | 36.12% |
| 2020 Q4 | 19.77 Billion KRW | -32.42% |
| 2020 Q3 | 29.26 Billion KRW | -19.11% |
| 2020 Q2 | 36.18 Billion KRW | 19.98% |
| 2019 FY | - KRW | 21.82% |
| 2019 Q4 | 16.26 Billion KRW | -29.45% |
| 2019 Q3 | 23.05 Billion KRW | 0.61% |
| 2019 Q1 | 22.48 Billion KRW | 45.65% |
| 2019 Q2 | 22.91 Billion KRW | 1.93% |
| 2018 Q2 | 20.94 Billion KRW | 19.88% |
| 2018 Q3 | 15.69 Billion KRW | -25.05% |
| 2018 Q4 | 15.43 Billion KRW | -1.68% |
| 2018 FY | - KRW | 9.71% |
| 2018 Q1 | 17.47 Billion KRW | 39.36% |
| 2017 FY | - KRW | -4.19% |
| 2017 Q4 | 12.53 Billion KRW | -26.65% |
| 2017 Q3 | 17.09 Billion KRW | -9.85% |
| 2017 Q2 | 18.95 Billion KRW | 28.01% |
| 2017 Q1 | 14.81 Billion KRW | -16.86% |
| 2016 FY | - KRW | 20.05% |
| 2016 Q4 | 17.81 Billion KRW | 7.1% |
| 2016 Q3 | 16.63 Billion KRW | -6.58% |
| 2016 Q2 | 17.8 Billion KRW | 21.63% |
| 2016 Q1 | 14.63 Billion KRW | 48.76% |
| 2015 Q3 | 13.3 Billion KRW | -12.58% |
| 2015 FY | - KRW | 9.08% |
| 2015 Q1 | 13.49 Billion KRW | 19.39% |
| 2015 Q2 | 15.21 Billion KRW | 12.75% |
| 2015 Q4 | 9.84 Billion KRW | -26.02% |
| 2014 FY | - KRW | 16.41% |
| 2014 Q4 | 11.3 Billion KRW | -11.92% |
| 2014 Q3 | 12.83 Billion KRW | -4.26% |
| 2014 Q2 | 13.4 Billion KRW | 9.55% |
| 2014 Q1 | 12.23 Billion KRW | 14.42% |
| 2013 Q1 | 10.29 Billion KRW | 94.41% |
| 2013 Q2 | 13.43 Billion KRW | 30.49% |
| 2013 FY | - KRW | 37.22% |
| 2013 Q4 | 10.69 Billion KRW | 5.91% |
| 2013 Q3 | 10.09 Billion KRW | -24.85% |
| 2012 Q3 | 6.16 Billion KRW | 22.36% |
| 2012 Q2 | 5.03 Billion KRW | 35.0% |
| 2012 Q4 | 5.29 Billion KRW | -14.01% |
| 2012 FY | - KRW | -14.02% |
| 2012 Q1 | 3.72 Billion KRW | 0.0% |
| 2011 Q2 | 7.19 Billion KRW | 18.68% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | - KRW | -6.5% |
| 2011 Q1 | 6.06 Billion KRW | 0.0% |
| 2011 Q3 | 5.04 Billion KRW | -29.91% |
| 2010 Q2 | 9.9 Billion KRW | 111.74% |
| 2010 FY | - KRW | 7.37% |
| 2010 Q1 | 4.67 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q3 | 1.47 Billion KRW | -85.06% |
| 2009 Q2 | 7.69 Billion KRW | 10.58% |
| 2009 Q1 | 6.95 Billion KRW | 0.0% |
| 2009 FY | - KRW | 13.35% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q3 | 4.35 Billion KRW | -43.35% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 FY | - KRW | 50.05% |
| 2008 Q2 | 5.27 Billion KRW | 24.04% |
| 2008 Q3 | 5.69 Billion KRW | 8.03% |
| 2008 Q1 | 4.25 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q3 | 4.51 Billion KRW | -7.64% |
| 2007 Q1 | 3.53 Billion KRW | 0.0% |
| 2007 Q2 | 4.89 Billion KRW | 38.37% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1485.49% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 45.511% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 220.289% |
| HANDOK Inc. | 35.06 Billion KRW | -119.663% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 7531.053% |
| Yuhan Corporation | 127.43 Billion KRW | 39.554% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -105.294% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 455.174% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 76.177% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -1443.556% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -409.507% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -2151.652% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -1601.759% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -117.065% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1485.49% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 517.005% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -1075.116% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 256.27% |
| JW Holdings Corporation | 187.88 Billion KRW | 59.002% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 250.362% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 72.842% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 13.665% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 307.81% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -483.125% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -551.246% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -312.914% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1485.49% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | -40.12% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 53.291% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 13.665% |
| Yuhan Corporation | 127.43 Billion KRW | 39.554% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -130.101% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -906.93% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 13.665% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -110.262% |
| Korea United Pharm Inc. | 70.78 Billion KRW | -8.828% |
| CKD Bio Corp. | -1.63 Billion KRW | 4824.386% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | -54.697% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -136.563% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -109.258% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 307.81% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | -23.672% |
| Boryung Corporation | 114.28 Billion KRW | 32.602% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 351.988% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -409.507% |
| JW Lifescience Corporation | 50.82 Billion KRW | -51.544% |